A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. (14th January 2014)
- Record Type:
- Journal Article
- Title:
- A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. (14th January 2014)
- Main Title:
- A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers
- Authors:
- Christmas, David
Diaper, Alison
Wilson, Sue
Rich, Ann
Phillips, Suzanne
Udo de Haes, Joanna
Sjogren, Magnus
Nutt, David - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hup2384-sec-0001" sec-type="section"> <title>Objective</title> <p>Cognitive impairment is integral to many neurological illnesses. Specific enhancement of glutamatergic transmission may improve memory and learning. Org 25935 increases the synaptic availability of glycine, an obligate co‐agonist with glutamate at <italic>N</italic>‐methyl‐<sc>d</sc>‐aspartate receptors. We hypothesised that Org 25935 would acutely improve the learning and memory of healthy volunteers.</p> </sec> <sec id="hup2384-sec-0002" sec-type="section"> <title>Methods</title> <p>A randomised, double‐blind, parallel‐group, single‐dose study of Org 25935 and placebo was carried out. Thirty‐two healthy male volunteers took either 12‐mg Org 25935 or matching placebo and were later assessed with the manikin task, digit span and verbal memory tests. Systematic assessments of cardiovascular and adverse events were also taken.</p> </sec> <sec id="hup2384-sec-0003" sec-type="section"> <title>Results</title> <p>There was no effect of Org 25935 on reaction time, number of correct responses or learning (greater or slower improvement over successive tasks) compared with placebo. Org 25935 caused significantly more dizziness and drowsiness compared with placebo; these side effects were mainly mild.</p> </sec> <sec id="hup2384-sec-0004" sec-type="section"> <title>Conclusions</title> <p>A single dose of Org 25935 does not<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hup2384-sec-0001" sec-type="section"> <title>Objective</title> <p>Cognitive impairment is integral to many neurological illnesses. Specific enhancement of glutamatergic transmission may improve memory and learning. Org 25935 increases the synaptic availability of glycine, an obligate co‐agonist with glutamate at <italic>N</italic>‐methyl‐<sc>d</sc>‐aspartate receptors. We hypothesised that Org 25935 would acutely improve the learning and memory of healthy volunteers.</p> </sec> <sec id="hup2384-sec-0002" sec-type="section"> <title>Methods</title> <p>A randomised, double‐blind, parallel‐group, single‐dose study of Org 25935 and placebo was carried out. Thirty‐two healthy male volunteers took either 12‐mg Org 25935 or matching placebo and were later assessed with the manikin task, digit span and verbal memory tests. Systematic assessments of cardiovascular and adverse events were also taken.</p> </sec> <sec id="hup2384-sec-0003" sec-type="section"> <title>Results</title> <p>There was no effect of Org 25935 on reaction time, number of correct responses or learning (greater or slower improvement over successive tasks) compared with placebo. Org 25935 caused significantly more dizziness and drowsiness compared with placebo; these side effects were mainly mild.</p> </sec> <sec id="hup2384-sec-0004" sec-type="section"> <title>Conclusions</title> <p>A single dose of Org 25935 does not improve learning or memory in healthy male individuals. However, the drug was well tolerated, and it remains to be seen whether it would have a positive effect on cognition in patient groups with pre‐existing cognitive deficits. Copyright © 2014 John Wiley &amp; Sons, Ltd.</p> </sec> </abstract> … (more)
- Is Part Of:
- Human psychopharmacology. Volume 29:Number 2(2014:Mar.)
- Journal:
- Human psychopharmacology
- Issue:
- Volume 29:Number 2(2014:Mar.)
- Issue Display:
- Volume 29, Issue 2 (2014)
- Year:
- 2014
- Volume:
- 29
- Issue:
- 2
- Issue Sort Value:
- 2014-0029-0002-0000
- Page Start:
- 163
- Page End:
- 171
- Publication Date:
- 2014-01-14
- Subjects:
- Psychopharmacology -- Periodicals
Psychotropic drugs -- Periodicals
Psychopharmacology -- Periodicals
Psychotropic Drugs -- pharmacology -- Periodicals
615.78 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/hup.2384 ↗
- Languages:
- English
- ISSNs:
- 0885-6222
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4336.380000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3278.xml